Association of serum pentraxin 3 levels with comorbidities in acute ischaemic stroke patients

Authors : Filiz Demirdöğen

Pages : 358-362

Doi:10.38053/acmj.1618793

View : 68 | Download : 73

Publication Date : 2025-05-30

Article Type : Research Paper

Abstract :Aims: Pentraxin 3 (PTX3), an indicator of the inflammatory process, is an acute-phase protein (AP) with biphasic effect. In the present study, the relationship between PTX3 levels and stroke risk factors in stroke patients were analyzed. Methods: Acute stroke patients (n=56) were diagnosed using imaging techniques and clinical examination along with and their laboratory results. The control group consisted of thirty healthy individuals. Blood samples of the patient group were obtained within the first 24 hours of stroke onset. Serum pentraxin levels of both groups were analyzed and their relationship with stroke risk factors evaluated. Results: A total of 86 people, 56 stroke patients and 30 healthy controls were included in the present study. Out of the participants, in both groups, 50% were female (p=1.000). No significant difference was determined between the groups in terms of age (p=0.226). The pentraxin value in the patient group was significantly lower than that in the control group (p=0.003). No significant difference between gender and presence of comorbidities in terms of PTX3 value (p>0.05) were present. Likewise, no significant correlation could be established between PTX3 value and National Institutes of Health Stroke Scale (NIHSS) and age in the patient group. Conclusion: Serum PTX3 can be used as a biomarker in acute stroke patients. However, it cannot be used as a predicator in determining prognosis during the acute period.
Keywords : Stroke, pentraxin 3, NIHSS, comorbidity

ORIGINAL ARTICLE URL